nodes	percent_of_prediction	percent_of_DWPC	metapath
Valsartan—hypertension—focal segmental glomerulosclerosis	0.446	1	CtDrD
Valsartan—AGTR1—focal segmental glomerulosclerosis	0.32	0.809	CbGaD
Valsartan—SLCO1B1—Cyclosporine—focal segmental glomerulosclerosis	0.0863	0.772	CbGbCtD
Valsartan—ALB—focal segmental glomerulosclerosis	0.0757	0.191	CbGaD
Valsartan—CYP2C9—Cyclosporine—focal segmental glomerulosclerosis	0.0255	0.228	CbGbCtD
Valsartan—AGTR1—nephron—focal segmental glomerulosclerosis	0.00472	0.446	CbGeAlD
Valsartan—AGTR1—endothelium—focal segmental glomerulosclerosis	0.00222	0.21	CbGeAlD
Valsartan—Tasosartan—AGTR2—focal segmental glomerulosclerosis	0.00153	0.341	CrCbGaD
Valsartan—ALB—Scavenging of heme from plasma—APOL1—focal segmental glomerulosclerosis	0.00133	0.0948	CbGpPWpGaD
Valsartan—AGTR1—ACE Inhibitor Pathway—AGTR2—focal segmental glomerulosclerosis	0.00102	0.0727	CbGpPWpGaD
Valsartan—AGTR1—nephron tubule—focal segmental glomerulosclerosis	0.00102	0.0963	CbGeAlD
Valsartan—Myositis—Cyclosporine—focal segmental glomerulosclerosis	0.000987	0.0555	CcSEcCtD
Valsartan—AGTR1—kidney—focal segmental glomerulosclerosis	0.000895	0.0846	CbGeAlD
Valsartan—Forasartan—AGTR1—focal segmental glomerulosclerosis	0.000874	0.195	CrCbGaD
Valsartan—AGTR1—cortex of kidney—focal segmental glomerulosclerosis	0.000871	0.0824	CbGeAlD
Valsartan—AGTR1—ACE Inhibitor Pathway—ACE—focal segmental glomerulosclerosis	0.000871	0.062	CbGpPWpGaD
Valsartan—SLCO1B1—kidney—focal segmental glomerulosclerosis	0.000853	0.0807	CbGeAlD
Valsartan—Serum creatinine increased—Cyclosporine—focal segmental glomerulosclerosis	0.000787	0.0442	CcSEcCtD
Valsartan—AGTR1—Angiopoietin receptor Tie2-mediated signaling—ANGPT2—focal segmental glomerulosclerosis	0.000604	0.043	CbGpPWpGaD
Valsartan—AGTR1—ACE Inhibitor Pathway—AGT—focal segmental glomerulosclerosis	0.000552	0.0393	CbGpPWpGaD
Valsartan—Rhabdomyolysis—Cyclosporine—focal segmental glomerulosclerosis	0.000547	0.0307	CcSEcCtD
Valsartan—Viral infection—Cyclosporine—focal segmental glomerulosclerosis	0.000536	0.0301	CcSEcCtD
Valsartan—ALB—Binding and Uptake of Ligands by Scavenger Receptors—APOL1—focal segmental glomerulosclerosis	0.000531	0.0378	CbGpPWpGaD
Valsartan—Tasosartan—AGTR1—focal segmental glomerulosclerosis	0.000529	0.118	CrCbGaD
Valsartan—SLCO1B3—Transport of organic anions—ALB—focal segmental glomerulosclerosis	0.000524	0.0373	CbGpPWpGaD
Valsartan—AGTR1—Arf6 signaling events—GNAQ—focal segmental glomerulosclerosis	0.000481	0.0343	CbGpPWpGaD
Valsartan—Hyperkalaemia—Cyclosporine—focal segmental glomerulosclerosis	0.000475	0.0267	CcSEcCtD
Valsartan—Blood urea increased—Cyclosporine—focal segmental glomerulosclerosis	0.000457	0.0257	CcSEcCtD
Valsartan—Olmesartan—AGTR1—focal segmental glomerulosclerosis	0.000447	0.0998	CrCbGaD
Valsartan—SLCO1B3—Recycling of bile acids and salts—ALB—focal segmental glomerulosclerosis	0.000388	0.0276	CbGpPWpGaD
Valsartan—Renal impairment—Cyclosporine—focal segmental glomerulosclerosis	0.000369	0.0207	CcSEcCtD
Valsartan—Dermatitis bullous—Cyclosporine—focal segmental glomerulosclerosis	0.000368	0.0207	CcSEcCtD
Valsartan—Cardiac failure—Cyclosporine—focal segmental glomerulosclerosis	0.00036	0.0202	CcSEcCtD
Valsartan—SLCO1B1—Transport of organic anions—ALB—focal segmental glomerulosclerosis	0.000352	0.0251	CbGpPWpGaD
Valsartan—Irbesartan—AGTR1—focal segmental glomerulosclerosis	0.000348	0.0776	CrCbGaD
Valsartan—Candesartan—AGTR1—focal segmental glomerulosclerosis	0.000348	0.0776	CrCbGaD
Valsartan—Blood creatinine increased—Cyclosporine—focal segmental glomerulosclerosis	0.000329	0.0185	CcSEcCtD
Valsartan—Abdominal pain upper—Cyclosporine—focal segmental glomerulosclerosis	0.000321	0.018	CcSEcCtD
Valsartan—Cramp muscle—Cyclosporine—focal segmental glomerulosclerosis	0.000316	0.0178	CcSEcCtD
Valsartan—AGTR1—Peptide GPCRs—AGTR2—focal segmental glomerulosclerosis	0.000314	0.0224	CbGpPWpGaD
Valsartan—Muscular weakness—Cyclosporine—focal segmental glomerulosclerosis	0.00031	0.0174	CcSEcCtD
Valsartan—Bronchitis—Cyclosporine—focal segmental glomerulosclerosis	0.000292	0.0164	CcSEcCtD
Valsartan—Upper respiratory tract infection—Cyclosporine—focal segmental glomerulosclerosis	0.000282	0.0159	CcSEcCtD
Valsartan—ALB—Binding and Uptake of Ligands by Scavenger Receptors—COL4A1—focal segmental glomerulosclerosis	0.000273	0.0195	CbGpPWpGaD
Valsartan—Infestation—Cyclosporine—focal segmental glomerulosclerosis	0.000271	0.0152	CcSEcCtD
Valsartan—Infestation NOS—Cyclosporine—focal segmental glomerulosclerosis	0.000271	0.0152	CcSEcCtD
Valsartan—AGTR1—ACE Inhibitor Pathway—TGFB1—focal segmental glomerulosclerosis	0.000268	0.0191	CbGpPWpGaD
Valsartan—Renal failure—Cyclosporine—focal segmental glomerulosclerosis	0.000266	0.015	CcSEcCtD
Valsartan—SLCO1B1—Recycling of bile acids and salts—ALB—focal segmental glomerulosclerosis	0.000261	0.0186	CbGpPWpGaD
Valsartan—Epistaxis—Cyclosporine—focal segmental glomerulosclerosis	0.000255	0.0144	CcSEcCtD
Valsartan—Sinusitis—Cyclosporine—focal segmental glomerulosclerosis	0.000254	0.0143	CcSEcCtD
Valsartan—Haemoglobin—Cyclosporine—focal segmental glomerulosclerosis	0.000244	0.0137	CcSEcCtD
Valsartan—Rhinitis—Cyclosporine—focal segmental glomerulosclerosis	0.000244	0.0137	CcSEcCtD
Valsartan—Hepatitis—Cyclosporine—focal segmental glomerulosclerosis	0.000243	0.0137	CcSEcCtD
Valsartan—Haemorrhage—Cyclosporine—focal segmental glomerulosclerosis	0.000243	0.0137	CcSEcCtD
Valsartan—Pharyngitis—Cyclosporine—focal segmental glomerulosclerosis	0.000241	0.0136	CcSEcCtD
Valsartan—Urinary tract disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00024	0.0135	CcSEcCtD
Valsartan—Connective tissue disorder—Cyclosporine—focal segmental glomerulosclerosis	0.000239	0.0134	CcSEcCtD
Valsartan—Urethral disorder—Cyclosporine—focal segmental glomerulosclerosis	0.000238	0.0134	CcSEcCtD
Valsartan—ALB—Lipoprotein metabolism—LIPC—focal segmental glomerulosclerosis	0.000225	0.016	CbGpPWpGaD
Valsartan—Losartan—AGTR1—focal segmental glomerulosclerosis	0.000224	0.05	CrCbGaD
Valsartan—Angiopathy—Cyclosporine—focal segmental glomerulosclerosis	0.000221	0.0124	CcSEcCtD
Valsartan—Mediastinal disorder—Cyclosporine—focal segmental glomerulosclerosis	0.000219	0.0123	CcSEcCtD
Valsartan—AGTR1—Angiopoietin receptor Tie2-mediated signaling—FN1—focal segmental glomerulosclerosis	0.000215	0.0153	CbGpPWpGaD
Valsartan—Alopecia—Cyclosporine—focal segmental glomerulosclerosis	0.000215	0.0121	CcSEcCtD
Valsartan—Mental disorder—Cyclosporine—focal segmental glomerulosclerosis	0.000213	0.012	CcSEcCtD
Valsartan—Malnutrition—Cyclosporine—focal segmental glomerulosclerosis	0.000212	0.0119	CcSEcCtD
Valsartan—Flatulence—Cyclosporine—focal segmental glomerulosclerosis	0.000208	0.0117	CcSEcCtD
Valsartan—ALB—Platelet degranulation—ACTN4—focal segmental glomerulosclerosis	0.000207	0.0148	CbGpPWpGaD
Valsartan—Dysgeusia—Cyclosporine—focal segmental glomerulosclerosis	0.000207	0.0116	CcSEcCtD
Valsartan—Muscle spasms—Cyclosporine—focal segmental glomerulosclerosis	0.000203	0.0114	CcSEcCtD
Valsartan—SLCO1B3—Bile acid and bile salt metabolism—ALB—focal segmental glomerulosclerosis	0.000203	0.0144	CbGpPWpGaD
Valsartan—Vision blurred—Cyclosporine—focal segmental glomerulosclerosis	0.000199	0.0112	CcSEcCtD
Valsartan—ALB—Response to elevated platelet cytosolic Ca2+—ACTN4—focal segmental glomerulosclerosis	0.000198	0.0141	CbGpPWpGaD
Valsartan—SLCO1B3—Transport of vitamins, nucleosides, and related molecules—ALB—focal segmental glomerulosclerosis	0.000194	0.0138	CbGpPWpGaD
Valsartan—Angioedema—Cyclosporine—focal segmental glomerulosclerosis	0.000193	0.0109	CcSEcCtD
Valsartan—AGTR1—Allograft Rejection—CD40LG—focal segmental glomerulosclerosis	0.000192	0.0137	CbGpPWpGaD
Valsartan—Vertigo—Cyclosporine—focal segmental glomerulosclerosis	0.00019	0.0107	CcSEcCtD
Valsartan—Cough—Cyclosporine—focal segmental glomerulosclerosis	0.000185	0.0104	CcSEcCtD
Valsartan—AGTR1—Angiopoietin receptor Tie2-mediated signaling—MMP2—focal segmental glomerulosclerosis	0.000182	0.013	CbGpPWpGaD
Valsartan—Myalgia—Cyclosporine—focal segmental glomerulosclerosis	0.00018	0.0101	CcSEcCtD
Valsartan—Chest pain—Cyclosporine—focal segmental glomerulosclerosis	0.00018	0.0101	CcSEcCtD
Valsartan—Arthralgia—Cyclosporine—focal segmental glomerulosclerosis	0.00018	0.0101	CcSEcCtD
Valsartan—Anxiety—Cyclosporine—focal segmental glomerulosclerosis	0.000179	0.0101	CcSEcCtD
Valsartan—Unspecified disorder of skin and subcutaneous tissue—Cyclosporine—focal segmental glomerulosclerosis	0.000179	0.0101	CcSEcCtD
Valsartan—Dry mouth—Cyclosporine—focal segmental glomerulosclerosis	0.000176	0.0099	CcSEcCtD
Valsartan—Anaphylactic shock—Cyclosporine—focal segmental glomerulosclerosis	0.000173	0.0097	CcSEcCtD
Valsartan—Oedema—Cyclosporine—focal segmental glomerulosclerosis	0.000173	0.0097	CcSEcCtD
Valsartan—Infection—Cyclosporine—focal segmental glomerulosclerosis	0.000172	0.00964	CcSEcCtD
Valsartan—Nervous system disorder—Cyclosporine—focal segmental glomerulosclerosis	0.000169	0.00952	CcSEcCtD
Valsartan—Thrombocytopenia—Cyclosporine—focal segmental glomerulosclerosis	0.000169	0.0095	CcSEcCtD
Valsartan—Skin disorder—Cyclosporine—focal segmental glomerulosclerosis	0.000168	0.00943	CcSEcCtD
Valsartan—Anorexia—Cyclosporine—focal segmental glomerulosclerosis	0.000165	0.00925	CcSEcCtD
Valsartan—Musculoskeletal discomfort—Cyclosporine—focal segmental glomerulosclerosis	0.000157	0.00884	CcSEcCtD
Valsartan—Insomnia—Cyclosporine—focal segmental glomerulosclerosis	0.000156	0.00878	CcSEcCtD
Valsartan—Paraesthesia—Cyclosporine—focal segmental glomerulosclerosis	0.000155	0.00871	CcSEcCtD
Valsartan—Dyspnoea—Cyclosporine—focal segmental glomerulosclerosis	0.000154	0.00865	CcSEcCtD
Valsartan—Somnolence—Cyclosporine—focal segmental glomerulosclerosis	0.000154	0.00863	CcSEcCtD
Valsartan—Dyspepsia—Cyclosporine—focal segmental glomerulosclerosis	0.000152	0.00854	CcSEcCtD
Valsartan—AGTR1—G alpha (q) signalling events—TRPC6—focal segmental glomerulosclerosis	0.000151	0.0107	CbGpPWpGaD
Valsartan—Decreased appetite—Cyclosporine—focal segmental glomerulosclerosis	0.00015	0.00844	CcSEcCtD
Valsartan—ALB—Lipid and lipoprotein metabolism—LIPC—focal segmental glomerulosclerosis	0.000149	0.0106	CbGpPWpGaD
Valsartan—Gastrointestinal disorder—Cyclosporine—focal segmental glomerulosclerosis	0.000149	0.00838	CcSEcCtD
Valsartan—Fatigue—Cyclosporine—focal segmental glomerulosclerosis	0.000149	0.00837	CcSEcCtD
Valsartan—AGTR1—Peptide ligand-binding receptors—AGTR2—focal segmental glomerulosclerosis	0.000148	0.0105	CbGpPWpGaD
Valsartan—Constipation—Cyclosporine—focal segmental glomerulosclerosis	0.000148	0.0083	CcSEcCtD
Valsartan—Gastrointestinal pain—Cyclosporine—focal segmental glomerulosclerosis	0.000141	0.00793	CcSEcCtD
Valsartan—ALB—Lipoprotein metabolism—LPL—focal segmental glomerulosclerosis	0.000137	0.00977	CbGpPWpGaD
Valsartan—Urticaria—Cyclosporine—focal segmental glomerulosclerosis	0.000137	0.00771	CcSEcCtD
Valsartan—Abdominal pain—Cyclosporine—focal segmental glomerulosclerosis	0.000136	0.00767	CcSEcCtD
Valsartan—SLCO1B1—Bile acid and bile salt metabolism—ALB—focal segmental glomerulosclerosis	0.000136	0.0097	CbGpPWpGaD
Valsartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—TRPC6—focal segmental glomerulosclerosis	0.000135	0.0096	CbGpPWpGaD
Valsartan—SLCO1B1—Transport of vitamins, nucleosides, and related molecules—ALB—focal segmental glomerulosclerosis	0.00013	0.00929	CbGpPWpGaD
Valsartan—Losartan—ACE—focal segmental glomerulosclerosis	0.000129	0.0289	CrCbGaD
Valsartan—Hypersensitivity—Cyclosporine—focal segmental glomerulosclerosis	0.000127	0.00715	CcSEcCtD
Valsartan—AGTR1—G alpha (q) signalling events—GNAQ—focal segmental glomerulosclerosis	0.000126	0.00897	CbGpPWpGaD
Valsartan—Asthenia—Cyclosporine—focal segmental glomerulosclerosis	0.000124	0.00696	CcSEcCtD
Valsartan—Pruritus—Cyclosporine—focal segmental glomerulosclerosis	0.000122	0.00687	CcSEcCtD
Valsartan—Diarrhoea—Cyclosporine—focal segmental glomerulosclerosis	0.000118	0.00664	CcSEcCtD
Valsartan—AGTR1—GPCRs, Class A Rhodopsin-like—AGTR2—focal segmental glomerulosclerosis	0.000116	0.00825	CbGpPWpGaD
Valsartan—Dizziness—Cyclosporine—focal segmental glomerulosclerosis	0.000114	0.00642	CcSEcCtD
Valsartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—GNAQ—focal segmental glomerulosclerosis	0.000113	0.00802	CbGpPWpGaD
Valsartan—Vomiting—Cyclosporine—focal segmental glomerulosclerosis	0.00011	0.00617	CcSEcCtD
Valsartan—Rash—Cyclosporine—focal segmental glomerulosclerosis	0.000109	0.00612	CcSEcCtD
Valsartan—Dermatitis—Cyclosporine—focal segmental glomerulosclerosis	0.000109	0.00611	CcSEcCtD
Valsartan—Headache—Cyclosporine—focal segmental glomerulosclerosis	0.000108	0.00608	CcSEcCtD
Valsartan—Nausea—Cyclosporine—focal segmental glomerulosclerosis	0.000103	0.00576	CcSEcCtD
Valsartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—AGTR2—focal segmental glomerulosclerosis	9.92e-05	0.00707	CbGpPWpGaD
Valsartan—AGTR1—G alpha (q) signalling events—EDN1—focal segmental glomerulosclerosis	9.76e-05	0.00696	CbGpPWpGaD
Valsartan—AGTR1—Peptide ligand-binding receptors—EDN1—focal segmental glomerulosclerosis	9.64e-05	0.00687	CbGpPWpGaD
Valsartan—ALB—Platelet activation, signaling and aggregation—ACTN4—focal segmental glomerulosclerosis	9.2e-05	0.00655	CbGpPWpGaD
Valsartan—ALB—Lipid and lipoprotein metabolism—LPL—focal segmental glomerulosclerosis	9.12e-05	0.00649	CbGpPWpGaD
Valsartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—EDN1—focal segmental glomerulosclerosis	8.73e-05	0.00622	CbGpPWpGaD
Valsartan—AGTR1—G alpha (q) signalling events—AGT—focal segmental glomerulosclerosis	8.11e-05	0.00577	CbGpPWpGaD
Valsartan—AGTR1—Peptide ligand-binding receptors—AGT—focal segmental glomerulosclerosis	8e-05	0.0057	CbGpPWpGaD
Valsartan—AGTR1—Allograft Rejection—TGFB1—focal segmental glomerulosclerosis	7.84e-05	0.00558	CbGpPWpGaD
Valsartan—AGTR1—GPCR ligand binding—AGTR2—focal segmental glomerulosclerosis	7.55e-05	0.00538	CbGpPWpGaD
Valsartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—AGT—focal segmental glomerulosclerosis	7.25e-05	0.00516	CbGpPWpGaD
Valsartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—EDN1—focal segmental glomerulosclerosis	6.47e-05	0.00461	CbGpPWpGaD
Valsartan—ALB—Vitamin B12 Metabolism—SERPINE1—focal segmental glomerulosclerosis	5.9e-05	0.0042	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism of lipids and lipoproteins—LIPC—focal segmental glomerulosclerosis	5.56e-05	0.00396	CbGpPWpGaD
Valsartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—AGT—focal segmental glomerulosclerosis	5.37e-05	0.00382	CbGpPWpGaD
Valsartan—Losartan—ALB—focal segmental glomerulosclerosis	5.31e-05	0.0118	CrCbGaD
Valsartan—SLCO1B3—Transmembrane transport of small molecules—TRPC6—focal segmental glomerulosclerosis	5.13e-05	0.00366	CbGpPWpGaD
Valsartan—ALB—Platelet degranulation—FN1—focal segmental glomerulosclerosis	4.95e-05	0.00352	CbGpPWpGaD
Valsartan—AGTR1—GPCR ligand binding—EDN1—focal segmental glomerulosclerosis	4.92e-05	0.00351	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism of lipids and lipoproteins—CTGF—focal segmental glomerulosclerosis	4.9e-05	0.00349	CbGpPWpGaD
Valsartan—ALB—Folate Metabolism—SERPINE1—focal segmental glomerulosclerosis	4.8e-05	0.00342	CbGpPWpGaD
Valsartan—ALB—Hemostasis—ACTN4—focal segmental glomerulosclerosis	4.74e-05	0.00338	CbGpPWpGaD
Valsartan—ALB—Response to elevated platelet cytosolic Ca2+—FN1—focal segmental glomerulosclerosis	4.71e-05	0.00336	CbGpPWpGaD
Valsartan—ALB—Platelet activation, signaling and aggregation—TRPC6—focal segmental glomerulosclerosis	4.41e-05	0.00314	CbGpPWpGaD
Valsartan—AGTR1—GPCR downstream signaling—TRPC6—focal segmental glomerulosclerosis	4.29e-05	0.00306	CbGpPWpGaD
Valsartan—AGTR1—GPCR downstream signaling—AGTR2—focal segmental glomerulosclerosis	4.27e-05	0.00304	CbGpPWpGaD
Valsartan—SLCO1B3—SLC-mediated transmembrane transport—ALB—focal segmental glomerulosclerosis	4.17e-05	0.00297	CbGpPWpGaD
Valsartan—ALB—Platelet degranulation—SERPINE1—focal segmental glomerulosclerosis	4.12e-05	0.00293	CbGpPWpGaD
Valsartan—AGTR1—GPCR ligand binding—AGT—focal segmental glomerulosclerosis	4.09e-05	0.00291	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—COL4A4—focal segmental glomerulosclerosis	4.03e-05	0.00287	CbGpPWpGaD
Valsartan—ALB—Response to elevated platelet cytosolic Ca2+—SERPINE1—focal segmental glomerulosclerosis	3.92e-05	0.00279	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—TRPC6—focal segmental glomerulosclerosis	3.9e-05	0.00278	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—AGTR2—focal segmental glomerulosclerosis	3.88e-05	0.00276	CbGpPWpGaD
Valsartan—ALB—Selenium Micronutrient Network—SERPINE1—focal segmental glomerulosclerosis	3.81e-05	0.00272	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism of lipids and lipoproteins—LIPC—focal segmental glomerulosclerosis	3.74e-05	0.00266	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—COL4A1—focal segmental glomerulosclerosis	3.71e-05	0.00264	CbGpPWpGaD
Valsartan—ALB—Platelet activation, signaling and aggregation—GNAQ—focal segmental glomerulosclerosis	3.69e-05	0.00263	CbGpPWpGaD
Valsartan—AGTR1—GPCR downstream signaling—GNAQ—focal segmental glomerulosclerosis	3.59e-05	0.00256	CbGpPWpGaD
Valsartan—SLCO1B1—Transmembrane transport of small molecules—TRPC6—focal segmental glomerulosclerosis	3.45e-05	0.00246	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism of lipids and lipoproteins—LPL—focal segmental glomerulosclerosis	3.39e-05	0.00242	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism of lipids and lipoproteins—CTGF—focal segmental glomerulosclerosis	3.29e-05	0.00234	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—GNAQ—focal segmental glomerulosclerosis	3.26e-05	0.00232	CbGpPWpGaD
Valsartan—ALB—Hemostasis—ANGPT2—focal segmental glomerulosclerosis	3.18e-05	0.00226	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—COL4A3—focal segmental glomerulosclerosis	3.13e-05	0.00223	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism of lipids and lipoproteins—AGT—focal segmental glomerulosclerosis	2.9e-05	0.00207	CbGpPWpGaD
Valsartan—SLCO1B1—SLC-mediated transmembrane transport—ALB—focal segmental glomerulosclerosis	2.8e-05	0.002	CbGpPWpGaD
Valsartan—AGTR1—GPCR downstream signaling—EDN1—focal segmental glomerulosclerosis	2.78e-05	0.00198	CbGpPWpGaD
Valsartan—ALB—Platelet degranulation—TGFB1—focal segmental glomerulosclerosis	2.6e-05	0.00185	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—EDN1—focal segmental glomerulosclerosis	2.53e-05	0.0018	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—LIPC—focal segmental glomerulosclerosis	2.48e-05	0.00176	CbGpPWpGaD
Valsartan—ALB—Response to elevated platelet cytosolic Ca2+—TGFB1—focal segmental glomerulosclerosis	2.48e-05	0.00176	CbGpPWpGaD
Valsartan—AGTR1—GPCR downstream signaling—AGT—focal segmental glomerulosclerosis	2.31e-05	0.00165	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—TRPC6—focal segmental glomerulosclerosis	2.3e-05	0.00164	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—AGTR2—focal segmental glomerulosclerosis	2.29e-05	0.00163	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism of lipids and lipoproteins—LPL—focal segmental glomerulosclerosis	2.28e-05	0.00162	CbGpPWpGaD
Valsartan—ALB—Hemostasis—TRPC6—focal segmental glomerulosclerosis	2.28e-05	0.00162	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism of lipids and lipoproteins—ALB—focal segmental glomerulosclerosis	2.23e-05	0.00159	CbGpPWpGaD
Valsartan—ALB—Platelet activation, signaling and aggregation—FN1—focal segmental glomerulosclerosis	2.19e-05	0.00156	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—CTGF—focal segmental glomerulosclerosis	2.18e-05	0.00155	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—LIPC—focal segmental glomerulosclerosis	2.14e-05	0.00152	CbGpPWpGaD
Valsartan—SLCO1B3—Transmembrane transport of small molecules—ALB—focal segmental glomerulosclerosis	2.12e-05	0.00151	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—AGT—focal segmental glomerulosclerosis	2.1e-05	0.00149	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—GNAQ—focal segmental glomerulosclerosis	2.01e-05	0.00143	CbGpPWpGaD
Valsartan—ALB—Transmembrane transport of small molecules—TRPC6—focal segmental glomerulosclerosis	1.97e-05	0.0014	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism of lipids and lipoproteins—AGT—focal segmental glomerulosclerosis	1.95e-05	0.00139	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—GNAQ—focal segmental glomerulosclerosis	1.93e-05	0.00137	CbGpPWpGaD
Valsartan—ALB—Hemostasis—GNAQ—focal segmental glomerulosclerosis	1.9e-05	0.00136	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—CTGF—focal segmental glomerulosclerosis	1.88e-05	0.00134	CbGpPWpGaD
Valsartan—ALB—Platelet activation, signaling and aggregation—SERPINE1—focal segmental glomerulosclerosis	1.83e-05	0.0013	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—LIPC—focal segmental glomerulosclerosis	1.75e-05	0.00124	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—LIPC—focal segmental glomerulosclerosis	1.66e-05	0.00119	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—CTGF—focal segmental glomerulosclerosis	1.54e-05	0.0011	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—LPL—focal segmental glomerulosclerosis	1.51e-05	0.00108	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism of lipids and lipoproteins—ALB—focal segmental glomerulosclerosis	1.5e-05	0.00107	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—EDN1—focal segmental glomerulosclerosis	1.49e-05	0.00106	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—CTGF—focal segmental glomerulosclerosis	1.47e-05	0.00104	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—LPL—focal segmental glomerulosclerosis	1.45e-05	0.00103	CbGpPWpGaD
Valsartan—SLCO1B1—Transmembrane transport of small molecules—ALB—focal segmental glomerulosclerosis	1.42e-05	0.00101	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	1.37e-05	0.000977	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—GNAQ—focal segmental glomerulosclerosis	1.35e-05	0.000962	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—LPL—focal segmental glomerulosclerosis	1.3e-05	0.000928	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—AGT—focal segmental glomerulosclerosis	1.29e-05	0.000921	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—AGT—focal segmental glomerulosclerosis	1.24e-05	0.000883	CbGpPWpGaD
Valsartan—ALB—Platelet activation, signaling and aggregation—TGFB1—focal segmental glomerulosclerosis	1.15e-05	0.000821	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—FN1—focal segmental glomerulosclerosis	1.15e-05	0.000816	CbGpPWpGaD
Valsartan—ALB—Hemostasis—FN1—focal segmental glomerulosclerosis	1.13e-05	0.000806	CbGpPWpGaD
Valsartan—ALB—Hemostasis—NOS2—focal segmental glomerulosclerosis	1.12e-05	0.000796	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—AGT—focal segmental glomerulosclerosis	1.11e-05	0.000794	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—LPL—focal segmental glomerulosclerosis	1.07e-05	0.00076	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—LPL—focal segmental glomerulosclerosis	1.02e-05	0.000723	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—ALB—focal segmental glomerulosclerosis	9.92e-06	0.000707	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	9.53e-06	0.000679	CbGpPWpGaD
Valsartan—ALB—Metabolism—LIPC—focal segmental glomerulosclerosis	9.51e-06	0.000677	CbGpPWpGaD
Valsartan—ALB—Hemostasis—SERPINE1—focal segmental glomerulosclerosis	9.41e-06	0.000671	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—AGT—focal segmental glomerulosclerosis	9.12e-06	0.00065	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—AGT—focal segmental glomerulosclerosis	8.69e-06	0.000619	CbGpPWpGaD
Valsartan—ALB—Metabolism—CTGF—focal segmental glomerulosclerosis	8.37e-06	0.000596	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—LIPC—focal segmental glomerulosclerosis	7.78e-06	0.000554	CbGpPWpGaD
Valsartan—ALB—Metabolism—GNAQ—focal segmental glomerulosclerosis	7.71e-06	0.000549	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	7.3e-06	0.00052	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—ALB—focal segmental glomerulosclerosis	7e-06	0.000499	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—CTGF—focal segmental glomerulosclerosis	6.85e-06	0.000488	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—ALB—focal segmental glomerulosclerosis	6.67e-06	0.000475	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—GNAQ—focal segmental glomerulosclerosis	6.31e-06	0.00045	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	6.01e-06	0.000428	CbGpPWpGaD
Valsartan—ALB—Hemostasis—TGFB1—focal segmental glomerulosclerosis	5.94e-06	0.000423	CbGpPWpGaD
Valsartan—ALB—Metabolism—LPL—focal segmental glomerulosclerosis	5.8e-06	0.000413	CbGpPWpGaD
Valsartan—ALB—Metabolism—AGT—focal segmental glomerulosclerosis	4.96e-06	0.000354	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—LPL—focal segmental glomerulosclerosis	4.75e-06	0.000338	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—AGT—focal segmental glomerulosclerosis	4.06e-06	0.000289	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—ALB—focal segmental glomerulosclerosis	3.12e-06	0.000222	CbGpPWpGaD
